U.S. Markets closed

Merck Plans $300 Million Acquisition Of Vaccine-Focused Biotech

ALLISON GATLIN
Merck Plans $300 Million Acquisition Of Vaccine-Focused Biotech

Dow Jones component Merck, in an effort to bolster its vaccine offerings, will spend $300 million to buy Immune Design. Immune Design stock flew more than 300% as Merck rose a fraction.